NCT07501819

Sympathetic Ablation for Ventricular Arrhythmias

Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: SymKardia · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.

Detailed description

The autonomic nervous system controls cardiac activity, and sympathetic hyperactivity is an important factor in triggering and sustaining cardiac arrhythmias such as ventricular tachycardia (VT). The objective of this study is to evaluate a new treatment for VT that targets a specific nerve that is part of the sympathetic system. In an acute procedure, an ablation catheter will be inserted into the femoral artery and guided to locations near the heart. Radiofrequency energy will be delivered to ablate the neural targets, and the catheter will be removed. Patients will be subsequently followed to determine safety and post-ablation reduction in VT frequency.

Conditions

• Ventricular Tachycardia (VT)

Interventions

Type	Name	Description
DEVICE	Central sympathetic nerve ablation	Catheter-based ablation of an extra-cardiac nerve target

Timeline

• Start date: 2026-04-01
• Primary completion: 2026-12-01
• Completion: 2027-09-01
• First posted: 2026-03-30
• Last updated: 2026-03-30

Regulatory

• FDA-regulated device study